{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:02:25Z","timestamp":1791349345037,"version":"4.3.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astra Zeneca"},{"name":"Eli Lilly"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["Pfizer"],"award-info":[{"award-number":["Pfizer"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11060-024-04902-0","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T10:05:43Z","timestamp":1734689143000},"page":"31-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal\u00a0metastatic disease"],"prefix":"10.1007","volume":"172","author":[{"given":"Jie Wei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maleeha A.","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dankner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Menjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Lim-Fat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"7","key":"4902_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41568-024-00700-y","volume":"24","author":"J Remsik","year":"2024","unstructured":"Remsik J, Boire A (2024) The path to leptomeningeal metastasis. Nat Rev Cancer 24(7):448\u2013460. https:\/\/doi.org\/10.1038\/s41568-024-00700-y","journal-title":"Nat Rev Cancer"},{"key":"4902_CR2","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D et al (2017) EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28:iv84\u2013iv99","journal-title":"Ann Oncol"},{"issue":"42","key":"4902_CR3","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, Lad SP, Fecci PE (2017) Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8(42):73312","journal-title":"Oncotarget"},{"issue":"1","key":"4902_CR4","doi-asserted-by":"publisher","first-page":"vdab162","DOI":"10.1093\/noajnl\/vdab162","volume":"3","author":"IA Tewarie","year":"2021","unstructured":"Tewarie IA, Jessurun CAC, Hulsbergen AFC et al (2021) Leptomeningeal disease in neurosurgical brain metastases patients: a systematic review and meta-analysis. Neurooncol Adv. 3(1):vdab162. https:\/\/doi.org\/10.1093\/noajnl\/vdab162","journal-title":"Neurooncol Adv."},{"issue":"8","key":"4902_CR5","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/neuonc\/noac023","volume":"24","author":"SR Lowe","year":"2022","unstructured":"Lowe SR, Wang CP, Brisco A et al (2022) Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. Neuro Oncol 24(8):1307\u20131317. https:\/\/doi.org\/10.1093\/neuonc\/noac023","journal-title":"Neuro Oncol"},{"issue":"4","key":"4902_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cancers13040732","volume":"13","author":"M Dankner","year":"2021","unstructured":"Dankner M, Lam S, Degenhard T et al (2021) The underlying biology and therapeutic vulnerabilities of leptomeningeal metastases in adult solid cancers. Cancers (Basel) 13(4):732. https:\/\/doi.org\/10.3390\/cancers13040732","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4902_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamaoncol.2022.7364","volume":"9","author":"AE Sharma","year":"2023","unstructured":"Sharma AE, Corbett K, Soliman H et al (2023) Assessment of phase 3 randomized clinical trials including patients with leptomeningeal disease: a systematic review. JAMA Oncol 9(4):566\u2013567. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7364","journal-title":"JAMA Oncol"},{"key":"4902_CR8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449\u20131454. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1a69","journal-title":"Neurology"},{"key":"4902_CR9","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","volume":"29","author":"JP Glass","year":"1979","unstructured":"Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369\u20131375. https:\/\/doi.org\/10.1212\/WNL.29.10.1369","journal-title":"Neurology"},{"issue":"8","key":"4902_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11912-023-01432-2","volume":"25","author":"MA Roy-O\u2019Reilly","year":"2023","unstructured":"Roy-O\u2019Reilly MA, Lanman T, Ruiz A, Rogawski D, Stocksdale B, Nagpal S (2023) Diagnostic and therapeutic updates in leptomeningeal disease. Curr Oncol Rep 25(8):937\u2013950. https:\/\/doi.org\/10.1007\/s11912-023-01432-2","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"4902_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/neuonc\/nov273","volume":"18","author":"B Milojkovic Kerklaan","year":"2016","unstructured":"Milojkovic Kerklaan B, Pluim D, Bol M et al (2016) EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro Oncol 18(6):855\u2013862","journal-title":"Neuro Oncol"},{"issue":"9","key":"4902_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","volume":"19","author":"X Lin","year":"2017","unstructured":"Lin X, Fleisher M, Rosenblum M et al (2017) Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro Oncol 19(9):1248\u20131254","journal-title":"Neuro Oncol"},{"issue":"4","key":"4902_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10585-015-9716-3","volume":"32","author":"D Subir\u00e1","year":"2015","unstructured":"Subir\u00e1 D, Sim\u00f3 M, Ill\u00e1n J et al (2015) Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. Clin Exp Metastasis 32(4):383\u2013391","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"4902_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/neuonc\/nor172","volume":"14","author":"D Subir\u00e1","year":"2012","unstructured":"Subir\u00e1 D, Serrano C, Casta\u00f1\u00f3n S et al (2012) Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro Oncol 14(1):43\u201352","journal-title":"Neuro Oncol"},{"issue":"2","key":"4902_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10549-015-3610-1","volume":"154","author":"JS Lee","year":"2015","unstructured":"Lee JS, Melisko ME, Magbanua MJ et al (2015) Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat 154(2):339\u2013349","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"4902_CR16","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.3390\/cancers13122888","volume":"13","author":"A Pellerino","year":"2021","unstructured":"Pellerino A, Brastianos PK, Rud\u00e0 R, Soffietti R (2021) Leptomeningeal metastases from solid tumors: recent advances in diagnosis and molecular approaches. Cancers (Basel) 13(12):2888. https:\/\/doi.org\/10.3390\/cancers13122888","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4902_CR17","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1038\/s41467-023-43242-x","volume":"14","author":"A Fitzpatrick","year":"2023","unstructured":"Fitzpatrick A, Iravani M, Mills A et al (2023) Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nat Commun 14(1):7408. https:\/\/doi.org\/10.1038\/s41467-023-43242-x","journal-title":"Nat Commun"},{"issue":"23","key":"4902_CR18","doi-asserted-by":"publisher","first-page":"7134","DOI":"10.1158\/0008-5472.CAN-13-2051","volume":"73","author":"MJ Magbanua","year":"2013","unstructured":"Magbanua MJ, Melisko M, Roy R et al (2013) Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res 73(23):7134\u20137143","journal-title":"Cancer Res"},{"issue":"2","key":"4902_CR19","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.18632\/oncotarget.23597","volume":"9","author":"X Li","year":"2018","unstructured":"Li X, Zhang Y, Ding J et al (2018) Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis. Oncotarget 9(2):2705\u20132714","journal-title":"Oncotarget"},{"issue":"18","key":"4902_CR20","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-17-0047","volume":"23","author":"BY Jiang","year":"2017","unstructured":"Jiang BY, Li YS, Guo WB et al (2017) Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res 23(18):5480\u20135488","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4902_CR21","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-21-3017","volume":"28","author":"A Fitzpatrick","year":"2022","unstructured":"Fitzpatrick A, Iravani M, Mills A et al (2022) Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis. Clin Cancer Res 28(6):1180\u20131191. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3017","journal-title":"Clin Cancer Res"},{"key":"4902_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12883-019-1554-5","volume":"19","author":"Y Zhao","year":"2019","unstructured":"Zhao Y et al (2019) Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis. BMC Neurol 19:331. https:\/\/doi.org\/10.1186\/s12883-019-1554-5","journal-title":"BMC Neurol"},{"issue":"1","key":"4902_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/1078-0432.CCR-17-1582","volume":"24","author":"Y Fan","year":"2018","unstructured":"Fan Y, Zhu X, Xu Y et al (2018) Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer. Clin Cancer Res 24(1):209\u2013216","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4902_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","volume":"29","author":"YS Li","year":"2018","unstructured":"Li YS, Jiang BY, Yang JJ et al (2018) Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol 29(4):945\u2013952","journal-title":"Ann Oncol"},{"key":"4902_CR25","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1073\/pnas.1511694112","volume":"112","author":"Y Wang","year":"2015","unstructured":"Wang Y, Springer S, Zhang M et al (2015) Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA 112:9704\u20139709. https:\/\/doi.org\/10.1073\/pnas.1511694112","journal-title":"Proc Natl Acad Sci USA"},{"key":"4902_CR26","doi-asserted-by":"publisher","unstructured":"Malhotra J, Muddasani R, Fricke J, et al. Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024;8:e2400373. https:\/\/doi.org\/10.1200\/PO-24-00373","DOI":"10.1200\/PO-24-00373"},{"key":"4902_CR27","doi-asserted-by":"publisher","first-page":"107292","DOI":"10.1016\/j.lungcan.2023.107292","volume":"182","author":"G Tsakonas","year":"2023","unstructured":"Tsakonas G, Tadigotla V, Chakrabortty SK et al (2023) Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer. Lung Cancer 182:107292. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107292","journal-title":"Lung Cancer"},{"issue":"5","key":"4902_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/1878-0261.13357","volume":"17","author":"J Wu","year":"2023","unstructured":"Wu J, Liu Z, Huang T et al (2023) Cerebrospinal fluid circulating Tumor DNA depicts profiling of brain Metastasis in NSCLC. Mol Oncol 17(5):810\u2013824. https:\/\/doi.org\/10.1002\/1878-0261.13357","journal-title":"Mol Oncol"},{"issue":"20","key":"4902_CR29","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","volume":"34","author":"EI Pentsova","year":"2016","unstructured":"Pentsova EI, Shah RH, Tang J et al (2016) Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 34(20):2404\u20132415","journal-title":"J Clin Oncol"},{"issue":"3","key":"4902_CR30","first-page":"451","volume":"19","author":"C Marchi\u00f2","year":"2017","unstructured":"Marchi\u00f2 C, Mariani S, Bertero L et al (2017) Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro Oncol 19(3):451\u2013453","journal-title":"Neuro Oncol"},{"key":"4902_CR31","unstructured":"Central Nervous System Cancers: Leptomeningeal Metastases 2022. Vol. v.1.2017 (2022)"},{"key":"4902_CR32","first-page":"42","volume":"3","author":"MC Chamberlain","year":"2001","unstructured":"Chamberlain MC, Kormanik PA, Glantz MJ (2001) A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 3:42\u201345","journal-title":"Neuro Oncol"},{"issue":"1","key":"4902_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-022-04118-0","volume":"160","author":"P Palmisciano","year":"2022","unstructured":"Palmisciano P, Watanabe G, Conching A et al (2022) Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials. J Neurooncol 160(1):79\u2013100. https:\/\/doi.org\/10.1007\/s11060-022-04118-0","journal-title":"J Neurooncol"},{"issue":"3","key":"4902_CR34","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.esmoop.2021.100150","volume":"6","author":"M Carausu","year":"2021","unstructured":"Carausu M, Carton M, Darlix A et al (2021) Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open 6(3):100150. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100150","journal-title":"ESMO Open"},{"key":"4902_CR35","doi-asserted-by":"publisher","first-page":"102653","DOI":"10.1016\/j.ctrv.2023.102653","volume":"122","author":"R Bartsch","year":"2024","unstructured":"Bartsch R, Jerzak KJ, Larrouquere L, M\u00fcller V, Le Rhun E (2024) Pharmacotherapy for leptomeningeal disease in breast cancer. Cancer Treat Rev 122:102653. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102653","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"4902_CR36","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.21873\/anticanres.15346","volume":"41","author":"P Palmisciano","year":"2021","unstructured":"Palmisciano P, Haider AS, Nwagwu CD et al (2021) The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review. Anticancer Res 41(11):5333\u20135342. https:\/\/doi.org\/10.21873\/anticanres.15346","journal-title":"Anticancer Res"},{"key":"4902_CR37","unstructured":"Zhu JW, Menjak IB, Saghal A, et al. Current approaches and future directions for the treatment of solid tumour brain metastases. Canadian Oncology Today. [Submitted for publication]"},{"issue":"9","key":"4902_CR38","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J et al (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28(9):1840\u20131847. https:\/\/doi.org\/10.1038\/s41591-022-01935-8","journal-title":"Nat Med"},{"issue":"1","key":"4902_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda JM, Vaz Batista M, Cortez P et al (2023) Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol 25(1):157\u2013166. https:\/\/doi.org\/10.1093\/neuonc\/noac144","journal-title":"Neuro Oncol"},{"key":"4902_CR40","doi-asserted-by":"crossref","unstructured":"377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03 Hurvitz, S.A. et al. Annals of Oncology, Volume 34, S335\u2013S336.","DOI":"10.1016\/j.annonc.2023.09.554"},{"key":"4902_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03261-7","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G et al (2024) Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03261-7","journal-title":"Nat Med"},{"key":"4902_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01614-1","author":"T Nakayama","year":"2024","unstructured":"Nakayama T, Niikura N, Yamanaka T et al (2024) Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and\/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). Breast Cancer. https:\/\/doi.org\/10.1007\/s12282-024-01614-1","journal-title":"Breast Cancer"},{"key":"4902_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.08.001","author":"M Vaz Batista","year":"2024","unstructured":"Vaz Batista M, P\u00e9rez-Garc\u00eda JM, Garrig\u00f3s L et al (2024) The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. https:\/\/doi.org\/10.1016\/j.medj.2024.08.001","journal-title":"Med"},{"issue":"3","key":"4902_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar PU, Avram MJ, Lassman AB et al (2023) A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol 25(3):557\u2013565. https:\/\/doi.org\/10.1093\/neuonc\/noac195","journal-title":"Neuro Oncol"},{"issue":"7","key":"4902_CR45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamaoncol.2024.1299.PMID:38780965;PMCID:PMC11117144","volume":"10","author":"KA Ahmed","year":"2024","unstructured":"Ahmed KA, Kumthekar PU, Pina Y, Kim Y, Vogelbaum MA, Han HS, Forsyth PA (2024) Radiation therapy followed by intrathecal trastuzumab-Pertuzumab for ERBB2-positive breast leptomeningeal disease: a phase 1 nonrandomized controlled trial. JAMA Oncol 10(7):984\u2013986. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1299.PMID:38780965;PMCID:PMC11117144","journal-title":"JAMA Oncol"},{"key":"4902_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.breast.2023.04.008","volume":"69","author":"AM Lazaratos","year":"2023","unstructured":"Lazaratos AM, Maritan SM, Quaiattini A et al (2023) Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast 69:451\u2013468. https:\/\/doi.org\/10.1016\/j.breast.2023.04.008","journal-title":"Breast"},{"key":"4902_CR47","doi-asserted-by":"crossref","unstructured":"Murthy RK, O\u2019Brien B, Berry D, et al (2022) Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study.\u00a0Cancer Research,\u00a082(4_Supplement), PD4-02","DOI":"10.1158\/1538-7445.SABCS21-PD4-02"},{"issue":"09","key":"4902_CR48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, ALEX Trial Investigators et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-smallcell lung cancer. N Engl J Med 377(09):829\u2013838","journal-title":"N Engl J Med"},{"issue":"10072","key":"4902_CR49","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open label, phase 3 study. Lancet 389(10072):917\u2013929","journal-title":"Lancet"},{"issue":"21","key":"4902_CR50","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, CROWN Trial Investigators et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018\u20132029","journal-title":"N Engl J Med"},{"issue":"23","key":"4902_CR51","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/JCO.24.00708","volume":"42","author":"S Park","year":"2024","unstructured":"Park S, Baldry R, Jung HA et al (2024) Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM). J Clin Oncol 42(23):2747\u20132756. https:\/\/doi.org\/10.1200\/JCO.24.00708","journal-title":"J Clin Oncol"},{"issue":"12","key":"4902_CR52","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS et al (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22(12):1692\u20131704. https:\/\/doi.org\/10.1016\/S1470-2045(21)00545-3","journal-title":"Lancet Oncol"},{"issue":"8","key":"4902_CR53","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos PK, Lee EQ, Cohen JV et al (2020) Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 26(8):1280\u20131284. https:\/\/doi.org\/10.1038\/s41591-020-0918-0. (Epub 2020 Jun 2. Erratum in: Nat Med. 2020;26(8):1309. 10.1038\/s41591-020-0978-1. PMID: 32483359)","journal-title":"Nat Med"},{"issue":"1","key":"4902_CR54","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","volume":"12","author":"PK Brastianos","year":"2021","unstructured":"Brastianos PK, Strickland MR, Lee EQ et al (2021) Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun 12(1):5954. https:\/\/doi.org\/10.1038\/s41467-021-25859-y","journal-title":"Nat Commun"},{"issue":"1","key":"4902_CR55","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","volume":"12","author":"SM Prakadan","year":"2021","unstructured":"Prakadan SM, Alvarez-Breckenridge CA, Markson SC et al (2021) Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases [published correction appears in Nat Commun. 2021 Nov 25;12(1):7007. 10.1038\/s41467-021-27207-6]. Nat Commun 12(1):5955. https:\/\/doi.org\/10.1038\/s41467-021-25860-5","journal-title":"Nat Commun"},{"issue":"1","key":"4902_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-023-00526-1","volume":"9","author":"KW Im","year":"2023","unstructured":"Im KW, Huppert LA, Malevanchik L et al (2023) High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease. NPJ Breast Cancer 9(1):22. https:\/\/doi.org\/10.1038\/s41523-023-00526-1","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"4902_CR57","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"IC Glitza Oliva","year":"2023","unstructured":"Glitza Oliva IC, Ferguson SD, Bassett R Jr et al (2023) Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results [published correction appears in Nat Med. 2024 Jun;30(6):1787. 10.1038\/s41591-024-02998-5]. Nat Med 29(4):898\u2013905. https:\/\/doi.org\/10.1038\/s41591-022-02170-x","journal-title":"Nat Med"},{"key":"4902_CR58","doi-asserted-by":"publisher","first-page":"1402651","DOI":"10.3389\/fonc.2024.1402651","volume":"14","author":"PU Kumthekar","year":"2024","unstructured":"Kumthekar PU, Blouw B, Corkos P et al (2024) The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy. Front Oncol 14:1402651. https:\/\/doi.org\/10.3389\/fonc.2024.1402651","journal-title":"Front Oncol"},{"issue":"1","key":"4902_CR59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12885-024-11975-7","volume":"24","author":"M Ben-Zion Berliner","year":"2024","unstructured":"Ben-Zion Berliner M, Yust-Katz S, Lavie I, Goldberg Y, Kedar I, Yerushalmi R (2024) Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis. BMC Cancer 24(1):219. https:\/\/doi.org\/10.1186\/s12885-024-11975-7","journal-title":"BMC Cancer"},{"issue":"3","key":"4902_CR60","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11060-023-04520-2","volume":"165","author":"Q Miao","year":"2023","unstructured":"Miao Q, Zheng X, Li L et al (2023) Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer. J Neurooncol 165(3):517\u2013525. https:\/\/doi.org\/10.1007\/s11060-023-04520-2","journal-title":"J Neurooncol"},{"issue":"1","key":"4902_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-023-04471-8","volume":"165","author":"K Bai","year":"2023","unstructured":"Bai K, Chen X, Qi X et al (2023) Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases. J Neurooncol 165(1):149\u2013160. https:\/\/doi.org\/10.1007\/s11060-023-04471-8","journal-title":"J Neurooncol"},{"key":"4902_CR62","doi-asserted-by":"publisher","first-page":"e15678","DOI":"10.7717\/peerj.15678","volume":"11","author":"F Hou","year":"2023","unstructured":"Hou F, Hou Y, Sun XD et al (2023) Establishment of a prognostic risk prediction model for non-small cell lung cancer patients with brain metastases: a retrospective study. PeerJ 11:e15678. https:\/\/doi.org\/10.7717\/peerj.15678","journal-title":"PeerJ"},{"issue":"1","key":"4902_CR63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12967-023-04077","volume":"21","author":"X Chen","year":"2023","unstructured":"Chen X, Bai K, Zhang Y et al (2023) Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer. J Transl Med 21(1):296. https:\/\/doi.org\/10.1186\/s12967-023-04077","journal-title":"J Transl Med"},{"key":"4902_CR64","doi-asserted-by":"publisher","first-page":"1322635","DOI":"10.3389\/fonc.2023.1322635","volume":"13","author":"X Liu","year":"2024","unstructured":"Liu X, Mei F, Fang M et al (2024) Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases. Front Oncol 13:1322635. https:\/\/doi.org\/10.3389\/fonc.2023.1322635","journal-title":"Front Oncol"},{"key":"4902_CR65","doi-asserted-by":"publisher","first-page":"103272","DOI":"10.1016\/j.esmoop.2024.103272","volume":"9","author":"L Larrouquere","year":"2024","unstructured":"Larrouquere L et al (2024) Genomic alterations of breast cancer patients with leptomeningeal disease: a retrospective analysis. ESMO Open 9:103272","journal-title":"ESMO Open"},{"issue":"16","key":"4902_CR66","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1200\/JCO.23.01621","volume":"42","author":"N Mikolajewicz","year":"2024","unstructured":"Mikolajewicz N, Yee PP, Bhanja D et al (2024) Systematic review of cerebrospinal fluid biomarker discovery in neuro-oncology: a roadmap to standardization and clinical application. J Clin Oncol 42(16):1961\u20131974. https:\/\/doi.org\/10.1200\/JCO.23.01621","journal-title":"J Clin Oncol"},{"key":"4902_CR67","doi-asserted-by":"publisher","first-page":"101688","DOI":"10.1016\/j.tranon.2023.101688","volume":"33","author":"RA Hickman","year":"2023","unstructured":"Hickman RA, Miller AM, Arcila ME (2023) Cerebrospinal fluid: a unique source of circulating tumor DNA with broad clinical applications. Transl Oncol 33:101688. https:\/\/doi.org\/10.1016\/j.tranon.2023.101688","journal-title":"Transl Oncol"},{"issue":"3","key":"4902_CR68","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1373\/clinchem.2014.235457","volume":"61","author":"W Pan","year":"2015","unstructured":"Pan W, Gu W, Nagpal S, Gephart MH, Quake SR (2015) Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 61(3):514\u2013522. https:\/\/doi.org\/10.1373\/clinchem.2014.235457","journal-title":"Clin Chem"},{"issue":"3","key":"4902_CR69","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1021\/acs.jproteome.8b00809","volume":"18","author":"L Dayon","year":"2019","unstructured":"Dayon L, Cominetti O, Wojcik J et al (2019) Proteomes of paired human cerebrospinal fluid and plasma: relation to blood-brain barrier permeability in older adults. J Proteome Res 18(3):1162\u20131174. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00809","journal-title":"J Proteome Res"},{"issue":"1","key":"4902_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41698-024-00582-1","volume":"8","author":"TD Azad","year":"2024","unstructured":"Azad TD, Nanjo S, Jin MC et al (2024) Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. NPJ Precis Oncol 8(1):121. https:\/\/doi.org\/10.1038\/s41698-024-00582-1","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"4902_CR71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/neuonc\/noz012","volume":"21","author":"A Boire","year":"2019","unstructured":"Boire A, Brandsma D, Brastianos PK et al (2019) Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol 21(5):571\u2013584. https:\/\/doi.org\/10.1093\/neuonc\/noz012","journal-title":"Neuro Oncol"},{"key":"4902_CR72","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.clbc.2021.11.002","volume":"22","author":"M Wooster","year":"2022","unstructured":"Wooster M et al (2022) Diagnosis of leptomeningeal metastasis in women with breast cancer through identification of tumor cells in cerebrospinal fluid using the CNSide assay. Clin Breast Cancer 22:e457\u2013e462. https:\/\/doi.org\/10.1016\/j.clbc.2021.11.002","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"4902_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","volume":"128","author":"Y Li","year":"2016","unstructured":"Li Y, Pan W, Connolly ID et al (2016) Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol 128(1):93\u2013100. https:\/\/doi.org\/10.1007\/s11060-016-2081-5","journal-title":"J Neurooncol"},{"issue":"11","key":"4902_CR74","doi-asserted-by":"publisher","first-page":"e1090","DOI":"10.1002\/ctm2.1090","volume":"12","author":"LJ Albrecht","year":"2022","unstructured":"Albrecht LJ, H\u00f6wner A, Griewank K et al (2022) Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype. Clin Transl Med 12(11):e1090. https:\/\/doi.org\/10.1002\/ctm2.1090","journal-title":"Clin Transl Med"},{"issue":"1","key":"4902_CR75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41698-021-00228-6","volume":"5","author":"Y Li","year":"2021","unstructured":"Li Y, Polyak D, Lamsam L et al (2021) Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases. NPJ Precis Oncol 5(1):90. https:\/\/doi.org\/10.1038\/s41698-021-00228-6","journal-title":"NPJ Precis Oncol"},{"issue":"14","key":"4902_CR76","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","volume":"27","author":"I Smalley","year":"2021","unstructured":"Smalley I, Chen Z, Phadke M et al (2021) Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Clin Cancer Res 27(14):4109\u20134125. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1694","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4902_CR77","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-19-2840","volume":"26","author":"I Smalley","year":"2020","unstructured":"Smalley I, Law V, Wyatt C et al (2020) Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance. Clin Cancer Res 26(9):2163\u20132175. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2840","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4902_CR78","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","volume":"168","author":"A Boire","year":"2017","unstructured":"Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massagu\u00e9 J (2017) Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168(6):1101-1113.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.02.025","journal-title":"Cell"},{"issue":"2","key":"4902_CR79","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.15350","volume":"158","author":"D Schmid","year":"2021","unstructured":"Schmid D, Warnken U, Latzer P et al (2021) Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. J Neurochem 158(2):522\u2013538. https:\/\/doi.org\/10.1111\/jnc.15350","journal-title":"J Neurochem"},{"key":"4902_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03286-y","author":"JA Zuccato","year":"2024","unstructured":"Zuccato JA, Mamatjan Y, Nassiri F et al (2024) Prediction of brain metastasis development with DNA methylation signatures. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03286-y","journal-title":"Nat Med"},{"issue":"1","key":"4902_CR81","doi-asserted-by":"publisher","first-page":"vdae052","DOI":"10.1093\/noajnl\/vdae052","volume":"6","author":"L Alder","year":"2024","unstructured":"Alder L, Broadwater G, Green M et al (2024) Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases. Neurooncol Adv 6(1):vdae052. https:\/\/doi.org\/10.1093\/noajnl\/vdae052","journal-title":"Neurooncol Adv"},{"issue":"6501","key":"4902_CR82","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.aaz2193","volume":"369","author":"Y Chi","year":"2020","unstructured":"Chi Y, Remsik J, Kiseliovas V et al (2020) Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science 369(6501):276\u2013282. https:\/\/doi.org\/10.1126\/science.aaz2193","journal-title":"Science"},{"key":"4902_CR83","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00122.10.1200\/PO.18.00122","author":"PK Mangat","year":"2018","unstructured":"Mangat PK, Halabi S, Bruinooge SS et al (2018) Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00122.10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04902-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04902-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04902-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:12:42Z","timestamp":1739830362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04902-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["4902"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04902-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.S. reports: grants from Elekta, Varian, Seagen Inc., BrainLAB, consulting fees from Varian, Elekta, BrainLAB, Merck, Abbvie, Roche, honoraria from AstraZeneca, Elekta, Varian, BrainLAB, Accuray, Seagen Inc., travel expenses from Elekta, Varian, BrainLAB, roles on leadership board as Vice President of International Stereotactic Radiosurgery Society and other interests as member of Elekta MR-Linac Research Consortium, member of Elekta Clinical Steering Committee, chair of Elekta Oligometastases Group and Elekta Gamma Knife Icon Group.\u00a0S.D. reports grant funding from the Canadian Institutes of Health Research, Gratitude 10, the Canadian Cancer Society, the Calum Macbeth fund, Synaptive, VPIX, and the Keenan Chair in Surgery,\u00a0royalties from Oxford University Press, travel and accommodation from the Congress of Neurological Surgeons and the American Association of Neurological Surgeons, data safety monitoring board or advisory board for the Subcortical Surgery Group, and is the Provincial Lead for CNS Cancers at Ontario Health, Cancer Care Ontario. I.M. reports:\u00a0honoraria from AstraZeneca and Merck, education funding from AstraZeneca.\u00a0M.L. reports: Advisory Board for Servier, Novocure.\u00a0K.J.J has been a consultant, speaker, or advisory board member for Amgen, AstraZeneca, Apo Biologix, Daiichi Sankyo, Eli Lilly, Esai, Genomic Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics, Novartis,\u00a0Organon, Pfizer, Roche,\u00a0and Viatris; has received research funding from AstraZeneca, Eli Lilly, and Pfizer; has received support for attending meetings or travel from AstraZeneca and Daiichi Sankyo; has a patent regarding compounds for treating cancer and methods of use thereof (US patent 10 576 056; Europe patent 3 393 466); and has received drug supply from Pfizer and\u00a0Viatris for an investigator initiated clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}